Inter-individual variability in drug response, be it efficacy or safety, is common and likely to
become an increasing problem globally given the growing elderly population requiring …

Polygenic scores (PGSs) have emerged as promising tools for complex trait risk prediction.
The application of these scores to pharmacogenomics provides new opportunities to …

Precision medicine provides patients with access to personally tailored treatments based on
individual-level data. However, developing personalized therapies requires analyses with …

The causes of variation in toxicity to the same treatment regimen among seemingly similar
patients remain largely unknown. There was tremendous optimism that the patient's …

The origins of pharmacogenetics date back to the 1950s, when it was established that inter-
individual differences in drug response are partially determined by genetic factors. Since …

Genome-wide significant loci for metformin response in type 2 diabetes reported elsewhere
have not been replicated in the Diabetes Prevention Program (DPP). To assess …

Chronic pelvic pain (CPP) in women with no obvious pelvic pathology has few evidence-
based treatment options. Our recent multicenter randomized controlled trial (GaPP2) in …

Cardiovascular disease is the leading cause of death worldwide, and it commonly results
from atherosclerotic plaque progression. One of the increasingly recognized drivers of …

The recent advances in high‐throughput next‐generation sequencing technologies have
heralded the arrival of the Big Data era. As a result, the use of pharmacogenetics in drug …

Psoriasis is an autoimmune cutaneous condition that significantly impacts quality of life and
represents a burden on society due to its prevalence. Genome-wide association studies …